Paris

• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• A Phase 3 Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Recruiting
  2022-502629-16-00 5 2024-07-10 Hemolytic Disease of the Fetus and Newborn (HDFN)
• Adjuvant therapy in high risk adrenocortical carcinoma (ADIUVO-2) Recruiting
  2022-500013-32-01 5 2024-07-05 Adrenocortical carcinoma
• Talazoparib plus Enzalutamide after progression to prior ARPi in Metastatic Prostate Cancer Recruiting
  2023-510536-37-00 4 2024-07-05 Prostate Cancer
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• CBD-OH - Cannabidiol as an add-on treatment during inpatient alcohol cessation in patients with severe alcohol use disorder: a Phase II tria … Recruiting
  2024-518455-28-00 4 2024-07-03 Patients with severe Alcohol Use Disorder (according to DSM 5) at entr
• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i … Recruiting
  2023-508204-38-00 5 2024-07-02 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• The NIPA study: A randomized double-blind control clinical trial Naloxegol administration to prevent opioids induced gastrointestinal motili … Recruiting
  2024-512004-19-01 5 2024-07-02 Head trauma
• An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617 … Recruiting
  2022-502956-29-00 5 2024-07-01 Oligometastatic prostate cancer (OMPC)
• “Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent n … Recruiting
  2023-505112-38-00 11 2024-07-01 recently active non-infectious intermediate, posterior, and pan-uveiti
• HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT) Recruiting
  2022-500210-26-00 5 2024-06-28 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Ovulation induction and luteal phase support with GnRH agonists in in vitro fertilization Recruiting
  2023-505126-34-00 5 2024-06-27 IVF (In vitro fertilization) or ICSI (intracytoplasmic sperm injection
• TRAUMACELL - Effects of intravascular administration of mesenchymal stromal cells derived from Wharton’s Jelly of the umbilical cord on syst … Recruiting
  2023-504415-33-00 9 2024-06-25 Patients aged 15 years and 3 months and older with severe head trauma
• Evaluation of the effectiveness of hormonal treatment in adolescents suffering from gender dysphoria Recruiting
  2024-513250-30-00 5 2024-06-25 gender dysphoria
• Personalized medicine for advanced biliary cancer patients Recruiting
  2023-508100-38-00 5 2024-06-24 Advanced Biliary Cancer (ABC)
• Preemptive Treament with acyclovir in intubated and mechanically ventilated patients with Herpes simplex virus oropharyngeal reactivation a … Recruiting
  2023-505510-26-00 5 2024-06-19 Patients in ICU with invasive mechanical ventilation and HSV throat re
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can … Recruiting
  2023-507914-28-00 10 2024-06-19 Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
• CARMOD - Golcadomide (BMS-986369) post-CAR T-cell in R/R Aggressive large B-cell lymphoma patients with high risk of relapse Recruiting
  2023-506705-20-00 4 2024-06-14 relapsed or refractory patients with aggressive large B-cell lymphoma
• FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting
  2023-506590-35-00 4 2024-06-13 Large-Cell NeuroEndocrine Carcinoma of the lung
• Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials – p53abn - RED Randomized phase … Recruiting
  2023-503886-44-00 5 2024-06-10 Patients with a histological diagnosis of p53abn HREC, treated with cu
• PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting
  2023-505214-23-00 5 2024-06-07 colon carcinoma
• Randomized controlled trial in patients on long-term colchicine with colchicine-resistant familial Mediterranean fever (FMF) to evaluate the … Recruiting
  2023-506721-11-00 5 2024-06-04 Familial Mediterranean Fever (FMF)
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• Open-label, single-arm, non-controlled trial to evaluate the safety and tolerability of treprostinil sodium in children below the age of 18 … Recruiting
  2023-505082-91-00 5 2024-05-29 Pulmonary Arterial Hypertension (PAH)

Showing 937–960 of 2,286 trials